title: Prognostic and predictive markers in metastatic renal cell carcinoma.
authors.forename: Muhammad A
authors.initials: MA
authors.lastname: Khattak
authors.forename: Farrah
authors.initials: F
authors.lastname: Bakr
authors.forename: Marcin
authors.initials: M
authors.lastname: Krzystanek
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Szallasi
authors.forename: Marco
authors.initials: M
authors.lastname: Gerlinger
authors.forename: Claudio
authors.initials: C
authors.lastname: Santos
authors.forename: Charles
authors.initials: C
authors.lastname: Swanton
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Pickering
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gore
authors.forename: James M G
authors.initials: JM
authors.lastname: Larkin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D054316:Biomarkers, Pharmacological / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D020123:Sirolimus / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014157:Transcription Factors / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D014157:Transcription Factors; D007770:L-Lactate Dehydrogenase; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus